Boehringer Takes Out Option For Cystic Fibrosis Gene Therapy
The German major is making its first foray into gene therapy and is looking to license a new viral vector-based product that could create a new therapeutic pathway for CF patients, regardless of their mutations.
You may also be interested in...
Gene Therapy 'Vant' Unveiled As Dainippon, Roivant Finalize $3bn Deal
Japanese firm signs definitive agreement to acquire Roivant's interests in five 'vants' initially, including new gene therapy operation, as ex-Genentech president named head of new entity.
Early Stage Candidates Carving Out New Routes In Cystic Fibrosis
Scrip spoke to two companies from a fresh wave of innovators that are approaching drug development for cystic fibrosis from a new angle.
Vertex Set To Dominate Cystic Fibrosis Market For The Next Decade
Vertex is set to reap huge benefits from its triple combination program for cystic fibrosis over the next 10 years, potentially becoming the biggest selling drug in this disease, according to a new report from Datamonitor Healthcare.